Salidroside derivative, and preparation method therefor and use thereof
The preparation of hydroxyl-α-Radians through the hydroxylation reaction of hydroxylase on α-Radians was solved, and the problem of insufficient research on hydroxyl-α-Radians in the prior art was achieved, and its use in cosmetics and The function of scavenging free radicals and improving learning and memory in medicines shows potential therapeutic effects on Alzheimer's and Parkinson's.
Patent Information
- Application Number
- PCT/CN2024/095989
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-04
- Filing Date
- 2024-05-29
- Publication Date
- 2024-12-12
AI Technical Summary
There is a lack of research and application of hydroxy-α-Radiodisin in the prior art, and the existing radiodisin has limitations in scavenging free radicals and improving learning and memory disorders.
Hydroxyl-α-Radiodistin is prepared by hydroxylation reaction of α-Radiodistin by hydroxylase, and it is applied to cosmetics, health products and medicines, using it to eliminate free radicals and improve learning and memory functions.
Hydroxy-α-Radiodisin showed higher activity in scavenging DPPH free radicals and significantly improved the learning and memory levels of model mice, with potential application in the treatment of Alzheimer's and Parkinson's.
Smart Images

Figure CN2024095989_12122024_PF_FP_ABST
Abstract
Description
Salidroside derivatives, preparation methods and applications
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] The present invention claims priority to Chinese patent application CN202310670529.3, filed on June 8, 2023, entitled “A salidroside derivative, preparation method, and use thereof,” and claims priority to Chinese patent application CN202410159803.5, filed on February 24, 2024, entitled “Salidroside derivative, preparation method, and use thereof.” The entire contents of the aforementioned applications are incorporated herein by reference for all purposes. Technical Field
[0003] The present invention relates to a salidroside derivative, in particular to a hydroxy-α-salidroside compound. Background Art
[0004] The information disclosed in this background technology section is only intended to enhance understanding of the overall background of the invention and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to those skilled in the art.
[0005] Rhodiola rosea is a precious traditional Chinese medicine. The 2020 edition of the Chinese Pharmacopoeia includes the dried roots and rhizomes of Rhodiola rosea of the Crassulaceae family. It is produced in Tibet and other places in China and grows in areas with an altitude of about 4050 to 5400 meters. Medicines such as Rhodiola rosea tablets and Xinnaoxin capsules prepared from Rhodiola rosea have the effects of promoting blood circulation and removing blood stasis, dredge meridians and relieve pain. The functions of health foods such as Rhodiola rosea capsules are to enhance immunity and relieve physical fatigue. Salidroside is the effective active ingredient of the traditional Chinese medicine Rhodiola rosea. It is reported that salidroside has physiological activities such as protecting cardiovascular and cerebrovascular vessels, anti-fatigue, anti-depression, anti-aging, anti-hypoxia, anti-radiation, anti-tumor, immune regulation, whitening and freckle removal. Salidroside in its natural state (plant-derived salidroside) is β-salidroside, and its glycosidic bond is β-type.
[0006] Chinese patent 202211359878.5 discloses an α-salidroside and its preparation method and application. The α-salidroside has a chemical name of 2-(4-hydroxyphenyl)ethyl-α-D-glucoside, a molecular weight of 300.23, and a chemical formula as follows. It has excellent free radical scavenging activity and can be used as the main raw material for cosmetics, anti-fatigue health products and other products.
[0007] Summary of the Invention
[0008] Purpose of the Invention: Driven by the need for product iteration, the applicant conducted research on salidroside and its derivatives, obtaining hydroxy-α-salidroside. Furthermore, the present invention provides a preparation method and application of hydroxy-α-salidroside.
[0009] There is no report on hydroxy-α-salidroside in the prior art.
[0010] Technical solution:
[0011] In a first aspect, the present invention provides a hydroxy-α-salidroside compound, chemical name: 2-(3,4-dihydroxyphenyl)ethyl-α-D-glucoside, chemical formula shown in Formula I, which has an α-glucoside bond on the alcoholic hydroxyl group of hydroxytyrosol.
[0012] The molecular weight of the hydroxy-α-salidroside of the present invention is 316.108 according to LC-MS analysis.
[0013] The H-NMR spectrum of the hydroxy-α-salidroside described in the present invention is as follows: 1HNMR (600 MHz, DMSO): δ2.64-2.72 (m, 2H), 3.02-3.08 (m, 1H), 3.17-3.21 (m, 1H), 3.31-3.37 (m, 4H), 3.37-3.46 (m, 2H), 3.46-3.51 (m, 1H), 3.57-3.63 (m, 1H), 3.67-3.73 (m, 1H), 4.44 (t, 1H), 4.57 (d, 1H), 4.68 (d, J=3.6 Hz, 1H: β-H), 4.73 (d, 1H), 4.83 (d, 1H), 8.64 (s, 1H: OH), 8.69 (s, 1H: OH).
[0014] The C-NMR spectrum of the hydroxy-α-salidroside: 13C NMR (151 MHz, DMSO): δ 35.5, 61.4, 68.9, 70.8, 72.5, 73.3, 73.8, 99.1, 115.9, 116.7, 120.0, 129.9, 144.0, 145.5.
[0015] In a second aspect, the present invention provides a method for preparing the hydroxy-α-salidroside compound.
[0016] The preparation method comprises dissolving α-salidroside in a buffer solution, adding hydroxylase, and performing a hydroxylation reaction in a reaction system to prepare the salidroside.
[0017] Preferably, the hydroxylase can be selected from commercially available hydroxylase preparations.
[0018] Further preferably, the commercially available hydroxylase enzyme preparations are derived from Merck & Co., Ltd., Shanghai MacLean Biochemical Technology Co., Ltd. and Shanghai Yuanye Biotechnology Co., Ltd., including but not limited to monophenol monooxygenase, polyphenol oxidase, tyrosinase, etc.
[0019] Preferably, a surfactant that does not affect the enzymatic reaction, such as polysorbate (Tween-20) or sorbitan fatty acid ester (Span), may be added to the reaction system.
[0020] In the present invention, the preparation of the hydroxy-α-salidroside can also be carried out in an organic solvent. The organic solvent used in the reaction can be any type and concentration range that does not affect the reaction, specifically including one solvent selected from DMSO, 2-propanol, and ethanol, or a mixed solvent of two or more.
[0021] Preferably, the reaction system contains ammonium salt.
[0022] The ammonium salt preferably includes but is not limited to ammonium chloride, ammonium acetate, or ammonium sulfate.
[0023] Ammonium salt can improve the conversion rate of substrate α-salidroside.
[0024] In a third aspect, the present invention provides the use of the hydroxy-α-salidroside compound in the preparation of products with free radical scavenging function; or the use of the hydroxy-α-salidroside compound in cosmetics with whitening function.
[0025] Preferably, the free radical is a 1,1-diphenyl-2-trinitrophenylhydrazine (DPPH) free radical.
[0026] In the application, preferably, the product is a cosmetic with the function of scavenging free radicals.
[0027] Preferably, the product with free radical scavenging function is a functional food.
[0028] The present invention further provides a composition containing hydroxy-α-salidroside.
[0029] Preferably, the composition has the function of scavenging free radicals or whitening skin.
[0030] Preferably, the free radical is a DPPH free radical.
[0031] The cosmetic composition containing hydroxy-α-salidroside is selected from aqueous solutions, oils, emulsions, gel products, paste products, or others, and can be produced according to existing cosmetic technical specifications.
[0032] The functional food composition containing hydroxy-α-salidroside has a dosage form selected from capsules, tablets, ointments, aqueous solutions, or others, and can be produced according to existing functional food technical specifications.
[0033] In a fourth aspect, the present invention also provides the use of the hydroxy-α-salidroside compound in the preparation of a drug for improving learning and memory disorders.
[0034] Preferably, the drugs for improving learning and memory disorders include but are not limited to drugs for treating Alzheimer's disease.
[0035] Preferably, the drugs for improving learning and memory disorders include but are not limited to drugs for treating Parkinson's disease.
[0036] Learning and memory impairments are a symptom cluster that can occur in many diseases. They can be caused by a variety of factors, including neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, stress, aging, ischemic brain injury, brain trauma, hypertension, diabetes, menopausal syndrome, and depression. Alzheimer's disease is the most common learning and memory impairment. Clinically available medications can only alleviate symptoms but cannot slow or halt its progression. Their efficacy varies from patient to patient and they are associated with numerous adverse reactions. Furthermore, the accelerated pace of work and life, increased competitive pressure, and chronic stress can lead to imbalances in coordination and function, particularly affecting cognitive function in the brain and resulting in decreased learning and memory abilities. Therefore, there is an urgent need for medications to improve learning and memory impairments. Studies have found that the hydroxy-α-salidroside described in the present invention has the ability to improve the learning and memory levels of model mice, as shown by significantly increasing the relative discrimination index of rats for objects in new locations, shortening the platform-finding latency in a water maze experiment, increasing the number of platform crossings, and reducing the number of errors and dark room time in a dark avoidance experiment, indicating that hydroxy-α-salidroside can effectively improve learning and memory disorders.
[0037] In a fifth aspect, a method for scavenging free radicals is provided, comprising administering an effective amount of hydroxy-α-salidroside or a composition comprising an effective amount of hydroxy-α-salidroside to a target area or a subject, wherein the free radical is a DPPH free radical.
[0038] In a sixth aspect, a method for whitening skin is provided, comprising applying an effective amount of hydroxy-α-salidroside or a composition comprising an effective amount of hydroxy-α-salidroside to the skin.
[0039] In a seventh aspect, a method for improving learning and memory disorders is provided, comprising administering to a subject an effective amount of hydroxy-α-salidroside or a composition comprising an effective amount of hydroxy-α-salidroside.
[0040] The "subject" of the present invention refers to any organism that needs treatment, prevention or diagnosis, preferably a mammal, more preferably a human.
[0041] As used herein, an "effective amount" refers to an amount of a compound sufficient to achieve the desired therapeutic, preventive, or diagnostic effect. This amount can be adjusted based on the subject's age, weight, health status, sex, and the specific therapeutic, preventive, or diagnostic purpose. The effective amount can be determined by conventional pharmacological test methods, in vitro tests, animal model tests, or clinical trials. Typically, the effective amount is in the range of about 0.01 mg / kg to 1000 mg / kg body weight, more preferably in the range of about 0.1 mg / kg to 100 mg / kg body weight. Beneficial effects:
[0042] The present invention provides a salidroside derivative, namely hydroxy-α-salidroside, which has higher activity in scavenging DPPH free radicals than α-salidroside and can be added to cosmetics or health products as a new functional ingredient; the hydroxy-α-salidroside also has the excellent performance of improving the learning and memory levels of model mice and can be developed and applied as a drug for the preparation of Alzheimer's disease or Parkinson's disease drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] The accompanying drawings, which constitute part of the present invention, are provided to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are provided to explain the present invention and do not constitute undue limitations thereon. The embodiments of the present invention will be described in detail below with reference to the accompanying drawings, wherein:
[0044] Figure 1: TLC spectrum of the enzyme-catalyzed reaction solution of Example 1; in the figure, from left to right are lane 1 and lane 2; lane 1 is α-salidroside, and lane 2 is hydroxy-α-salidroside.
[0045] Figure 2: HPLC spectrum of the enzyme-catalyzed reaction solution of Example 1.
[0046] Figure 3: LC-MS spectrum of the substance at rt = 6.97 min in the HPLC spectrum of the enzyme-catalyzed reaction solution of Example 1.
[0047] Figure 4: H-NMR spectrum of the substance at rt = 6.97 min in the HPLC spectrum of the enzyme-catalyzed reaction solution of Example 1.
[0048] Figure 5: C-NMR spectrum of the substance at rt = 6.97 min in the HPLC spectrum of the enzyme-catalyzed reaction solution of Example 1. DETAILED DESCRIPTION
[0049] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions or as recommended by the manufacturer.
[0050] Unless otherwise defined, all professional and scientific terms used herein have the same meaning as those familiar to those skilled in the art. The reagents or raw materials used in the present invention can be purchased through conventional channels. Unless otherwise specified, the reagents or raw materials used in the present invention are used in a conventional manner in the art or according to the product instructions. In addition, any methods and materials similar to or equivalent to those described herein can be applied to the present invention. The preferred embodiments and materials described herein are for demonstration purposes only.
[0051] The hydroxy-α-salidroside of the present invention has a chemical name: 2-(3,4-dihydroxyphenyl)ethyl-α-D-glucoside, and its structural formula is shown in Formula I.
[0052] The preparation method of hydroxy-α-salidroside of the present invention uses α-salidroside as a substrate and realizes hydroxylation under the action of hydroxylase.
[0053] The hydroxylase can be selected from commercially available hydroxylase enzyme preparations from Merck & Co., Ltd., Shanghai MacLean Biochemical Technology Co., Ltd. and Shanghai Yuanye Biotechnology Co., Ltd., including catechol oxidase but not limited to monophenol monooxygenase, polyphenol oxidase, tyrosinase, etc.
[0054] The method of using the hydroxylase enzyme preparation includes adding it to the reaction system in the form of powder or liquid, and also fixing the enzyme preparation on a resin to make an immobilized enzyme preparation and adding it to the reaction system. The immobilized enzyme preparation can be reused.
[0055] The method for preparing hydroxy-α-salidroside of the present invention comprises adding hydroxylase to α-salidroside phosphate buffer to perform a hydroxylase reaction. A surfactant that does not affect the enzymatic reaction, such as Tween-20 and Span, may be added to the enzyme reaction solution.
[0056] When using the above-mentioned hydroxylase to prepare hydroxy-α-salidroside compounds, the amount of hydroxylase and reaction conditions have a great influence on the production efficiency, so it is crucial to select appropriate reaction conditions such as the amount of enzyme and reaction time.
[0057] The reaction can be carried out in the presence of a solvent. The solvent used in the reaction can be any solvent as long as it does not affect the reaction and its concentration range. Specifically, it can include common reagents such as DMSO, 2-propanol, and ethanol. These solvents can be used alone or in combination of two or more.
[0058] The enzyme used in the present invention can be inactivated by heating or changing the pH value, thereby stopping the enzyme catalytic reaction.
[0059] The mixture containing the hydroxy-α-salidroside compound, the hydrolyzate of the mixture, the enzyme-inactivated product of the mixture, and the purified product of the mixture, as well as their dried powder products, can be used in foods, beverages, and cosmetics containing the hydroxy-α-salidroside compound, and can also be used as ingredients in foods, special medical foods, health products, or medicines, and used in the production of foods and beverages, cosmetics, special medical foods, health products, or medicines.
[0060] TLC analysis conditions: The enzyme reaction solution was rapidly analyzed by thin layer chromatography. The specific analysis conditions were as follows: a TLC plate (Merck Kieselgel 60F254) produced by Merck was used, and a solution of chloroform:methanol:acetic acid = 5:1:1 was used as the developing solvent.
[0061] HPLC analysis conditions: high performance liquid chromatograph: Hitachi HPLC 5440 chromatograph, chromatographic column: Kromasil 100-5C18 (250*4.6 mm), detector: photodiode array (DAD 280 nm), detection wavelength: UV 280 nm, injection volume: 10 μL, flow rate: 1 mL / min, column temperature: 30°C, mobile phase: acetonitrile: 0.1% formic acid aqueous solution (v / v) isocratic elution.
[0062] LC-MS analysis conditions: chromatographic column: Kromasil 100-5C18 (250*4.6mm), detector: photodiode array (DAD 280nm), detection wavelength: 280nm, injection volume: 10μL, flow rate: 1mL / min, column temperature: 30℃, mobile phase with detection time of 5-15min; H-ESI mode, molecular weight scanning range: 50-800.
[0063] The document "Enzymatic routes for the production of mono- and di-glucosylated derivatives of hydroxytyrosol" by Antonio Trincone et al., Volume 115 of Bioresource Technology, is an article on "Enzymatic production of mono- and di-glucosylated derivatives of hydroxytyrosol." By adding a homogenate of visceral material from Aplysia fasciata to 1.5 mL of a 10 mM receptor solution in 50 mM potassium acetate buffer (pH 5.5, containing 150 mM maltose), a (3,4-dihydroxyphenyl)ethyl-α-D-glucopyranoside compound was obtained. The target compound was inferred from the NMR data obtained by acetylation of the reaction product. However, the document lacks mass spectrometry identification data and does not disclose the molecular weight of the specific compound. There is also no chemical shift data for the key hydrogen atoms of the α-glucoside, and the chemical structure of the specific compound is not disclosed, so the stereoconfiguration of the compound cannot be confirmed.
[0064] The inventors of the present invention acetylated the hydroxy-α-salidroside compound of the present invention according to the method described in the document, and then performed carbon spectrum and hydrogen spectrum analysis. However, they were unable to obtain the carbon spectrum and hydrogen spectrum data of the acetylated product and its supplementary document. Therefore, the hydroxy-α-salidroside compound obtained in the present invention is different from the compound obtained in the document.
[0065] Example 1. Tyrosinase hydroxylation experiment
[0066] 500 mg of α-salidroside (molecular weight 300.23) was added to 50 mL of 0.2 M phosphate buffer (and adjusted to pH 10), 500 mg of ascorbic acid, and 3 mg of tyrosinase (T828256-100KU, McLean), and water was added to make the volume to 100 mL. The mixture was stirred at 25°C for 24 hours to obtain an enzyme-catalyzed reaction solution.
[0067] Example 2. Polyphenol oxidase hydroxylation experiment
[0068] 100 mg of α-salidroside (molecular weight 300.23) was added to 50 mL of 0.2 M phosphate buffer (and adjusted to pH 10), 100 mg of ascorbic acid, and 3 mg of tyrosinase (S10171-100KU, Shanghai Yuanye Biotechnology Co., Ltd.). Water was added to make the volume to 100 mL, and the reaction was stirred at 15°C for 50 hours to obtain an enzyme-catalyzed reaction solution.
[0069] Example 3. Monophenol monooxygenase hydroxylation experiment
[0070] Take 500 mg of α-salidroside (molecular weight 300.23), add 50 mL of 0.2 M phosphate buffer (pH 9), add 500 mg of ascorbic acid, and then add 1.5 g of monophenol monooxygenase (T3824-50KU, Merck). Add water to make the volume to 100 mL, stir and react at 35°C for 24 hours to obtain an enzyme-catalyzed reaction solution.
[0071] Example 4. Monophenol monooxygenase hydroxylation experiment
[0072] According to the method described in Example 3, the feed amount was simultaneously increased by 10 times, and the reaction was stirred at 35° C. for 24 hours to obtain an enzyme-catalyzed reaction solution.
[0073] Example 5. Purification and structural analysis of hydroxy-α-salidroside
[0074] The reaction solutions of Examples 1-4 were analyzed by TLC, HPLC, LC-MS, and NMR.
[0075] (1) TLC analysis
[0076] The TLC analysis of the reaction solution of Example 1 is shown in Figure 1, which shows that a new substance is produced in the enzyme-catalyzed reaction solution. In the figure, from left to right, lanes 1 and 2 are respectively: lane 1 is α-salidroside, and lane 2 is the new substance produced by the enzyme-catalyzed reaction.
[0077] (2) HPLC analysis
[0078] According to the above chromatographic conditions, the purified reaction solution of Example 1 was subjected to HPLC analysis. The HPLC spectrum is shown in Figure 2.
[0079] The HPLC spectrum shown in Figure 2 shows that the reaction solution after purification in Example 1 mainly has two peaks, with peak elution times of rt = 6.97 min and rt = 9.98 min, respectively. The peak at rt = 9.98 min is α-salidroside, and the peak at rt = 6.97 min has a significant difference in elution time from that of α-salidroside.
[0080] (3) LC-MS analysis
[0081] LC-MS analysis was performed on the substance with rt=6.97 min in the HPLC spectrum of the reaction solution of Example 1, and the measured value of the molecular ion peak [M-1] was 315.108. The LC-MS spectrum is shown in Figure 3.
[0082] According to the UV spectrum and LC-MS spectrum displayed by the photodiode array detector, preliminary analysis of the new peak substance with a retention time of rt = 6.97 min in the HPLC spectrum showed a molecular weight of 316.108, which may be a glycoside formed by the hydroxylation of α-salidroside, possibly hydroxy-α-salidroside.
[0083] (4) Separation and purification
[0084] The enzyme-catalyzed reaction solution obtained in Example 1-4 was separated and purified by HPLC, and the material with rt = 6.97 min was collected. The equipment and conditions of the HPLC method included:
[0085] A semi-preparative high performance liquid chromatograph (BRIX 2850, Beijing Chengda Instrument Co., Ltd.) was used with a COSMOSIL 5C18-MS-II column (250*20 mm). The mobile phase was acetonitrile: 0.1% formic acid aqueous solution (v / v) at a ratio of 1:9 for isocratic elution. A photodiode array detector was used with a UV detection wavelength of 280 nm. The injection volume was 100 μL and the flow rate was 18 mL / min.
[0086] The collected substances with rt=6.97 min from Examples 1-4 were concentrated and freeze-dried to obtain freeze-dried solids, which were used as the target substances of Examples 1-4 for subsequent experiments.
[0087] (5) H-NMR and C-NMR spectrum analysis
[0088] The above freeze-dried samples were taken for H-NMR and C-NMR analysis.
[0089] The H-NMR spectrum of the substance at rt=6.97 min in the HPLC spectrum of the reaction solution of Example 1 is shown in FIG4 , and the C-NMR spectrum is shown in FIG5 .
[0090] 1H-NMR (600MHz, DMSO): δ2.64-2.72(m,2H),3.02-3.08(m,1H),3.17-3.2 1(m,1H),3.31-3.37(m,4H),3.37-3.46(m,2H),3.46-3.51(m,1H),3.57- 3.63(m,1H),3.67-3.73(m,1H),4.44(t,1H),4.57(d,1H),4.68(d,J=3.6 Hz,1H:β-H),4.73(d,1H),4.83(d,1H),8.64(s,1H:OH),8.69(s,1H:OH).
[0091] 13C-NMR (151MHz, DMSO): δ35.5,61.4,68.9,70.8,72.5,73.3,73.8,99.1,115.9,116.7,120.0,129.9,144.0,145.5.
[0092] According to the H-NMR and C-NMR spectra of the product in Example 1, combined with the H-NMR and C-NMR spectra of α-salidroside disclosed in Chinese patent application 202211359878.5, the H-NMR spectrum of the product in Example 1 has two singlets (s, 1H:OH) at 8.64ppm and 8.69ppm, which is "characteristic of bisphenolic hydroxyl groups." α-salidroside has a singlet at 9.10ppm, which is "characteristic of monophenolic hydroxyl groups." In addition, the C-NMR spectrum of the product in Example 1 has 14 characteristic peaks, while α-salidroside has only 12 characteristic peaks, which are significantly different.
[0093] In summary, from the TLC spectrum and HPLC spectrum, it can be seen that the enzyme-catalyzed reaction produces a new substance; from the LC-MS analysis, the molecular weight of the new substance is 316.108; combined with the H-NMR and C-NMR spectra, it is confirmed that the substance obtained by the enzyme-catalyzed reaction in Example 1 is hydroxy-α-salidroside.
[0094] The HPLC spectrum, LC-MS spectrum, H-NMR spectrum, and C-NMR spectrum of the product of the enzymatic reaction of Example 2-4 were the same as those of the reaction solution of Example 1. Therefore, the substance obtained by the enzymatic reaction of Example 2-4 was also hydroxy-α-salidroside.
[0095] The concentration of hydroxy-α-salidroside in the reaction solution of Example 1-4 was determined by HPLC. The results are recorded in Table 1.
[0096] Table 1
[0097] Example 6-8. Based on Example 3, an ammonium salt, such as ammonium chloride, ammonium acetate, or ammonium sulfate, is added to the reaction system to carry out an enzymatic reaction. The details are as follows:
[0098] 500 mg of α-salidroside (molecular weight 300.23) was taken, added to 50 mL of 0.2 M phosphate buffer (pH 9), added to 500 mg of ascorbic acid, and added to 10 mL of 0.2 M ammonium salt (specific ammonium salt varieties are shown in Table 2). Then, 1.5 g of monophenol monooxygenase (T3824-50KU, Merck) was added, and the volume was made up to 100 mL with water. The reaction was stirred at 35° C. for 24 hours to obtain an enzyme-catalyzed reaction solution. The hydroxy-α-salidroside in the reaction solution was detected by HPLC. The results are recorded in Table 2.
[0099] Table 2
[0100] The data in Table 2 show that both ammonium chloride and ammonium acetate can improve the conversion rate of the substrate α-salidroside in the enzymatic reaction.
[0101] Example 9. Free radical scavenging experiment. The materials and reagents used are shown in Table 3.
[0102] Table 3. Materials and reagents
[0103] DPPH Radical Scavenging Experiment: Free radicals exert strong oxidative effects, directly or indirectly, and are widely involved in physiological and pathological processes. Excessive free radicals can damage the body through oxidative damage. Salvianolic acids are phenolic hydroxyl group donors, providing the structural basis for their antioxidant activity. This experiment used the DPPH radical scavenging reaction to investigate the DPPH radical scavenging efficiency of hydroxy-α-salidroside, α-salidroside, and β-salidroside.
[0104] Solution preparation:
[0105] (1) Preparation of Hydroxy-α-Salidroside Solution: The target substances of Examples 1-3 were prepared according to the method of Example 5, and were prepared into 500 mg / L aqueous solutions according to conventional methods.
[0106] (2) Preparation of α-salidroside solution: Prepare a 500 mg / L aqueous solution according to conventional methods.
[0107] (3) Preparation of β-salidroside solution: Prepare a 500 mg / L aqueous solution according to conventional methods.
[0108] (4) Preparation of DPPH ethanol solution: Prepare a 0.04 mg / mL anhydrous ethanol solution according to conventional methods.
[0109] 2.DPPH free radical scavenging experiment:
[0110] (1) Take 0.9 mL of hydroxy-α-salidroside, α-salidroside, and β-salidroside aqueous solutions respectively, add 0.9 mL of DPPH anhydrous ethanol solution respectively, mix well, and place in a dark place for static. Samples are taken at 0.5 h, 1 h, 2 h, 3 h, 4 h, and 5 h respectively, and the absorbance is measured at a wavelength of 517 nm. The average value of three parallel samples is calculated and recorded as Ai.
[0111] (2) Take 0.9 mL of hydroxy-α-salidroside, α-salidroside, and β-salidroside aqueous solutions respectively, add 0.9 mL of anhydrous ethanol respectively, mix well, and place in a dark place for standing. Samples are taken at 0.5 h, 1 h, 2 h, 3 h, 4 h, and 5 h respectively, and the absorbance is measured at a wavelength of 517 nm. The average value of three parallel solutions is calculated and recorded as Aj.
[0112] (3) Take 0.9 mL of distilled water, add 0.9 mL of DPPH ethanol solution, mix well, measure the absorbance at a wavelength of 517 nm, and calculate the average value of three parallel measurements, which is recorded as A4.
[0113] (4) Add 0.9 mL of anhydrous ethanol to 0.9 mL of distilled water and mix well. This is used as a blank.
[0114] The DPPH free radical scavenging rate was calculated according to the following formula. The results are shown in Table 4.
[0115] Table 4. DPPH free radical scavenging rate
[0116] The data in Table 4 illustrate that the free radical scavenging ability of hydroxy α-salidroside reaches its highest value in 0.5 hours, which is more than 4 times that of α-salidroside and β-salidroside.
[0117] Example 10. Tyrosinase activity inhibition experiment
[0118] Materials and reagents are shown in Table 5.
[0119] Table 5. Materials and reagents
[0120] Instrument: 752N UV-visible spectrophotometer, Shanghai Youke Instrument Co., Ltd.
[0121] Solution preparation:
[0122] (1) Preparation of α-salidroside solution: Prepare a 1 mg / mL aqueous solution according to conventional methods.
[0123] (2) Preparation of Hydroxy-α-Salidroside Solution: The target substances of Examples 1-3 were prepared according to the method of Example 5, and were prepared into 1 mg / mL aqueous solutions according to conventional methods.
[0124] (3) Preparation of disodium hydrogen phosphate-citrate buffer:
[0125] 1) Prepare a 0.2 mol / L sodium hydrogen phosphate and 0.1 mol / L citric acid aqueous solution.
[0126] 2) Take 154.5 mL of sodium hydrogen phosphate aqueous solution and 45.5 mL of citric acid aqueous solution, mix well, and adjust the pH to 6.8 (measure with a pH meter; 0.2 mol / L sodium hydrogen phosphate or 0.1 mol / L citric acid can be used to adjust the pH).
[0127] (4) Preparation of tyrosinase solution: Prepare 100 u / mL tyrosinase solution using the above-mentioned sodium hydrogen phosphate-citrate buffer.
[0128] (5) Preparation of levodopa solution: Prepare 1 mg / mL levodopa solution using the above-mentioned sodium hydrogen phosphate-citrate buffer.
[0129] Experimental plan:
[0130] (1) Take 1 mL of hydroxy-α-salidroside solution and 1 mL of α-salidroside solution, add 0.5 mL of tyrosinase to each, mix well, and incubate in a 37°C water bath for 10 min. Then add 2 mL of levodopa to each solution, control the reaction time to 5 min, and immediately measure the absorbance T at 475 nm.
[0131] (2) Sample background T0: Take 1 mL of hydroxy-α-salidroside solution and 1 mL of α-salidroside solution, add 0.5 mL of sodium hydrogen phosphate-citrate buffer solution, mix well, and incubate in a 37°C water bath for 10 min. Then add 2 mL of levodopa, control the reaction time to 5 min, and immediately measure the absorbance at 475 nm.
[0132] (3) Enzyme reaction tube C: Take 1 mL of sodium hydrogen phosphate-citrate buffer, add 0.5 mL of tyrosinase, mix well, and incubate in a 37°C water bath for 10 min. Then add 2 mL of levodopa, control the reaction time to 5 min, and immediately measure the absorbance at 475 nm.
[0133] (4) Solvent background C0: Take 1.5 mL of sodium hydrogen phosphate-citrate buffer, incubate in a 37°C water bath for 10 min, add 2 mL of levodopa, control the reaction time to 5 min, and immediately measure the absorbance at 475 nm.
[0134] The inhibition rate of tyrosinase activity was calculated according to the following formula, and the results are recorded in Table 6.
[0135] Table 6
[0136] The data in Table 6 illustrate that the tyrosinase activity inhibition rate of the hydroxy-α-salidroside solution obtained in Example 1 and Example 3 is 46 times or more than that of α-salidroside.
[0137] Example 11. Experimental study on the effect of hydroxy-α-salidroside on learning and memory in Wistar rats
[0138] Experimental animals: 56 young male Wistar rats, weighing 290-315 g, were randomly divided into 4 groups, 14 rats in each group, and randomly divided into blank control group, AD model group 1, AD model group 2, and AD model group 3.
[0139] Hydroxy-α-salidroside sample solution: The target substance of Example 4 was prepared according to the method described in Example 5 and prepared into a 10 mg / mL solution.
[0140] α-Salidroside sample solution: α-Salidroside is the raw material for preparing hydroxy-α-Salidroside in the examples, and is prepared into a 10 mg / mL solution.
[0141] Experimental methods
[0142] Modeling: Establishment of AD model in Wistar male rats
[0143] AD model group 1-3 modeling method: Wistar male rats were intraperitoneally injected with 120 mg / kg of D-galactose and 80 mg / kg of sodium nitrite daily for 7 consecutive weeks to complete the modeling; the blank control group was intraperitoneally injected with an equal volume of normal saline.
[0144] The drugs were administered according to the following schedule starting on the second day after the end of the 7th week of modeling and continued for 30 days.
[0145] AD model group 1: Each rat was orally administered with hydroxy-α-salidroside sample solution once a day, with a dose of 5 mg per kg body weight.
[0146] AD model group 3: Each rat was orally gavaged with α-salidroside sample solution once a day, with a dose of 5 mg per kg body weight.
[0147] AD model group 2 and blank control group: rats were gavaged with the sample solution once a day, with the same volume of distilled water as that of AD model group 1.
[0148] 1. Water Maze Experiment
[0149] Starting from the 31st day, the Morris water maze test was performed, and the drug administration was continued according to the above scheme during the test.
[0150] The experimental heated swimming pool was 120 cm in diameter, 50 cm high, 30 cm deep, and maintained at a temperature of (22 ± 1)°C. Two objects were randomly hung on the pool wall as visual cues of close proximity. A built-in platform was 7 cm in diameter and submerged 2 cm below the surface of the water. Several small holes were placed on the platform to provide a stable surface for the rats.
[0151] The environmental information remained constant throughout the experiment. Milk was added to the pool to make the platform invisible. The maze was divided into four equal quadrants, with the platform placed in the center of one quadrant, providing the animals with only one way to escape the water.
[0152] On the first day of the Morris water maze test, rats were placed in a water pool (without a platform) and allowed to swim freely for 2 minutes to familiarize themselves with the environment in the maze.
[0153] Starting from the second day of the Morris water maze test, the platform was placed in a quadrant, and a positioning navigation test was performed, and the escape latency was recorded. The test was repeated for three consecutive days, three times a day, and the entry point was changed each time. The order of the entry points for all rats remained the same every day (clockwise). During the test, care should be taken to keep the platform position fixed. The other three quadrants without the platform were selected as the entry points for the rats, and the rats were gently placed in the water toward the pool wall. 120s was set as the longest escape latency, and the recording stopped automatically after 120s. If the rat found the platform within 120s, its actual escape latency was recorded; if the platform was not found within 120s, the experimenter led it to the platform and stayed there for 10s, and the escape latency was recorded as 120s.
[0154] The water maze escape latency of rats in each group was recorded, and the average daily escape latency of each group is recorded in Table 7.
[0155] Table 7 Results of rat water maze escape latency measurement
[0156] The Morris water maze test is an experiment that forces experimental animals (rats and mice) to swim and learn to find a platform hidden in the water. It is mainly used to test the learning and memory ability of experimental animals for spatial position and direction (spatial positioning).
[0157] Escape latency: Escape latency is the time it takes an animal to swim from its starting position in the water maze to locate the hidden platform. As the number of trials increases, the time it takes for an animal to find the platform should decrease, indicating progress in learning and remembering the platform's location. Longer escape latency may indicate impaired spatial learning and memory.
[0158] Table 7 Data Description:
[0159] (1) On the 2nd to 4th day of the navigation experiment, the escape latency of the AD1-3 group model rats was longer than that of the blank control group rats (P<0.05), indicating that the AD1-3 group model rats needed a longer time to find the underwater hidden platform.
[0160] (2) The AD model group 1 was the hydroxy-α-salidroside treatment group, and its escape latency was shorter than that of the AD model group 3 (α-salidroside treatment group) and the AD model group 2 (blank model group), indicating that the AD3 group model rats needed a shorter time to find the underwater hidden platform, and that hydroxy-α-salidroside had a certain effect on improving the spatial learning and memory ability of the AD model rats.
[0161] It should be noted that the above examples are only intended to illustrate the technical solutions of the present invention and are not intended to limit the same. Although the present invention has been described in detail with reference to the examples given, those skilled in the art may modify or replace the technical solutions of the present invention as needed without departing from the spirit and scope of the technical solutions of the present invention.
Claims
1. A hydroxy-α-salidroside, chemically named: 2-(3,4-dihydroxyphenyl)ethyl-α-D-glucoside, with a structural formula as shown in Formula I, 2. Use of the hydroxy-α-salidroside described in claim 1 in the preparation of a product having the function of scavenging free radicals; Preferably, the free radical is a DPPH free radical, and the product is a cosmetic or a functional food.
3. Use of the hydroxy-α-salidroside described in claim 1 in the preparation of products with whitening function.
4. Use of the hydroxy-α-salidroside according to claim 1 in the preparation of a medicine for improving learning and memory disorders; Preferably, the medicine for improving learning and memory disorders includes but is not limited to medicine for treating Alzheimer's disease; Preferably, the medicines for improving learning and memory disorders include but are not limited to medicines for treating Parkinson's disease.
5. A composition, characterized in that Contains the hydroxy-α-salidroside according to claim 1.
6. Use of the composition as claimed in claim 5 in scavenging free radicals.
7. Use of the composition as claimed in claim 5 in preparing whitening cosmetics.
8. Use of the composition according to claim 5 in the preparation of a medicine for improving learning and memory disorders; Preferably, the medicine for improving learning and memory disorders includes but is not limited to medicine for treating Alzheimer's disease; Preferably, the medicines for improving learning and memory disorders include but are not limited to medicines for treating Parkinson's disease.
9. The method for preparing hydroxy-α-salidroside according to claim 1, characterized in that: In a solution containing α-salidroside, hydroxylase is added to react; Preferably, the hydroxylase is selected from monophenol monooxygenase, polyphenol oxidase or tyrosinase.
10. The preparation method according to claim 9, characterized in that: Ammonium salt is also added to the reaction; Preferably, the ammonium salt is ammonium chloride, ammonium acetate or ammonium sulfate.
Citation Information
Patent Citations
Monoamine oxidase diagnostic reagent kit and method for measuring active concentration of monoamine oxidase
CN101464392A
New application of hydroxytyrosol and derivatives thereof in preparation of antidepressant products
CN109223734A
Glycosyl transferase for catalytic synthesis of hydroxyl salidroside as well as coding gene and application of glycosyl transferase
CN114317480A
Alpha-salidroside as well as preparation method and application thereof
CN115819479A
Salidroside derivative as well as preparation method and application thereof
CN116396342A
Cited By
Method for purifying and decolorizing salidroside fermentation liquor by combining macroporous adsorption resin and aluminum oxide chromatographic filler
CN120737136A
Method for producing high-purity salidroside from fermentation liquor through green purification
CN120842291A
